fluoxetine has been researched along with Multiple Sclerosis, Chronic Progressive in 8 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Multiple Sclerosis, Chronic Progressive: A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Foley, P | 1 |
| Parker, RA | 4 |
| de Angelis, F | 3 |
| Connick, P | 3 |
| Chandran, S | 3 |
| Young, C | 1 |
| Weir, CJ | 4 |
| Chataway, J | 4 |
| Plantone, D | 3 |
| Doshi, A | 3 |
| John, N | 2 |
| Stutters, J | 3 |
| MacManus, D | 3 |
| Prados Carrasco, F | 2 |
| Barkhof, F | 3 |
| Ourselin, S | 2 |
| Braisher, M | 2 |
| Ross, M | 2 |
| Cranswick, G | 2 |
| Pavitt, SH | 2 |
| Giovannoni, G | 2 |
| Gandini Wheeler-Kingshott, CA | 2 |
| Hawkins, C | 2 |
| Sharrack, B | 2 |
| Bastow, R | 2 |
| Stallard, N | 2 |
| Solanky, BS | 1 |
| John, NA | 1 |
| DeAngelis, F | 1 |
| Prados, F | 1 |
| Schneider, T | 1 |
| Monteverdi, A | 1 |
| Marshall, I | 1 |
| Gandini Wheeler-Kingshott, CAM | 1 |
| Sulehria, T | 1 |
| Corbett, AM | 1 |
| Sharma, N | 1 |
| Nagarajan, D | 1 |
| Abushamma, A | 1 |
| Gagle, S | 1 |
| Johnson, A | 1 |
| Cambron, M | 2 |
| Mostert, J | 2 |
| D'Hooghe, M | 2 |
| Nagels, G | 2 |
| Willekens, B | 2 |
| Debruyne, J | 2 |
| Algoed, L | 2 |
| Verhagen, W | 2 |
| Hupperts, R | 2 |
| Heersema, D | 2 |
| De Keyser, J | 3 |
| Haentjens, P | 1 |
| Van Hecke, W | 1 |
| De Klippel, N | 1 |
| Fosselle, E | 1 |
| Laureys, G | 1 |
| Merckx, H | 1 |
| Van Wijmeersch, B | 1 |
| Vanopdenbosch, L | 1 |
| Hengstman, G | 1 |
| Michiels, V | 1 |
| Van Merhaegen-Wieleman, A | 1 |
| Mostert, JP | 1 |
| Admiraal-Behloul, F | 1 |
| Hoogduin, JM | 1 |
| Luyendijk, J | 1 |
| Heersema, DJ | 1 |
| van Buchem, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.[NCT01910259] | Phase 2 | 445 participants (Actual) | Interventional | 2014-12-18 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for fluoxetine and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Topics: Adult; Amiloride; Double-Blind Method; Fluoxetine; Humans; Multiple Sclerosis; Multiple Sclerosis, C | 2022 |
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Topics: Administration, Oral; Adult; Amiloride; Brain; Disease Progression; Double-Blind Method; Female; Flu | 2020 |
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Topics: Adult; Amiloride; Aspartic Acid; Biomarkers; Child, Preschool; Cohort Studies; Cross-Sectional Studi | 2020 |
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple scl
Topics: Adult; Amiloride; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Multiple Scler | 2018 |
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
Topics: Adult; Aged; Belgium; Brain; Clinical Protocols; Cognition; Disability Evaluation; Disease Progressi | 2014 |
Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study.
Topics: Adult; Brain; Double-Blind Method; Female; Fluoxetine; Humans; Inflammation; Magnetic Resonance Imag | 2008 |
2 other studies available for fluoxetine and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
Increasing Progenitor Cell Proliferation in the Sub-Ventricular Zone: A Therapeutic Treatment for Progressive Multiple Sclerosis?
Topics: Animals; Ascorbic Acid; Cell Proliferation; Drug Therapy, Combination; Female; Fluoxetine; Lateral V | 2020 |
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
Topics: Clinical Trials, Phase II as Topic; Fluoxetine; Humans; Multiple Sclerosis, Chronic Progressive; Sel | 2019 |